DE69624436D1 - Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie - Google Patents

Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie

Info

Publication number
DE69624436D1
DE69624436D1 DE69624436T DE69624436T DE69624436D1 DE 69624436 D1 DE69624436 D1 DE 69624436D1 DE 69624436 T DE69624436 T DE 69624436T DE 69624436 T DE69624436 T DE 69624436T DE 69624436 D1 DE69624436 D1 DE 69624436D1
Authority
DE
Germany
Prior art keywords
cell line
pct
humaner
monoclonal antibody
human antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69624436T
Other languages
English (en)
Other versions
DE69624436T2 (de
Inventor
Chang Yuil Kang
Joong Gon Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Corp
Original Assignee
LG Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Chemical Co Ltd filed Critical LG Chemical Co Ltd
Application granted granted Critical
Publication of DE69624436D1 publication Critical patent/DE69624436D1/de
Publication of DE69624436T2 publication Critical patent/DE69624436T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69624436T 1995-04-08 1996-04-06 Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie Expired - Fee Related DE69624436T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19950008176 1995-04-08
PCT/KR1996/000045 WO1996032495A1 (en) 1995-04-08 1996-04-06 Monoclonal antibody specific for human 4-1bb and cell line producing same

Publications (2)

Publication Number Publication Date
DE69624436D1 true DE69624436D1 (de) 2002-11-28
DE69624436T2 DE69624436T2 (de) 2003-08-28

Family

ID=19411779

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69624436T Expired - Fee Related DE69624436T2 (de) 1995-04-08 1996-04-06 Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie

Country Status (9)

Country Link
US (1) US5928893A (de)
EP (1) EP0766745B1 (de)
JP (1) JP2911056B2 (de)
AT (1) ATE226641T1 (de)
DE (1) DE69624436T2 (de)
DK (1) DK0766745T3 (de)
ES (1) ES2185770T3 (de)
PT (1) PT766745E (de)
WO (1) WO1996032495A1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303121B1 (en) * 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US20060002904A9 (en) * 1988-11-07 2006-01-05 Kwon Byoung S Receptor and related products and methods
US6362325B1 (en) * 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US20060063923A1 (en) * 1992-07-30 2006-03-23 Kwon Byoung S 4-1BB peptides and methods for use
CA2172165C (en) * 1993-09-16 2003-12-02 Byoung S. Kwon Human receptor h4-1bb
US6210669B1 (en) * 1996-10-11 2001-04-03 Bristol-Myers Squibb Co. Methods and compositions for immunomodulation
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20030096976A1 (en) * 1998-11-17 2003-05-22 Hong Hyo Jeong Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
US20040001863A1 (en) * 1998-12-03 2004-01-01 Shau-Chi Chi Immortal cell line derived from grouper Epinephelus coioides and its applications therein
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
CA2408408C (en) 2000-05-12 2013-07-09 Genzyme Corporation Modulators of tnf- alpha signaling
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
DE60232895D1 (de) 2001-10-09 2009-08-20 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
CN1688603A (zh) * 2002-07-15 2005-10-26 马约医学教育与研究基金会 使用4－1bb结合剂的治疗和预防
PL375144A1 (en) * 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
EP1388544A1 (de) * 2002-07-31 2004-02-11 D. Collen Research Foundation vzw Anti-Idiotypische Antikörper gegen Factor VIII-Inhibitor und Verwendungen davon
US20040136992A1 (en) * 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
EP1575672A2 (de) * 2002-12-16 2005-09-21 Herbert Schwarz Verwendung von cd137-antagonisten zur behandlung von tumoren
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
JP5303146B2 (ja) 2004-10-06 2013-10-02 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
AU2006304886B2 (en) * 2005-10-21 2012-04-12 Genzyme Corporation Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
WO2009111315A2 (en) * 2008-02-29 2009-09-11 Mayo Foundation For Medical Education And Research Methods for reducing granulomatous inflammation
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
WO2011071883A1 (en) * 2009-12-07 2011-06-16 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
JP6162319B2 (ja) 2013-03-12 2017-07-12 デシミューン セラピューティクス，インコーポレイテッド ヒト化抗ｎ２抗体
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
ES2714708T3 (es) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
ES2783026T3 (es) 2014-02-04 2020-09-16 Pfizer Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
JP2018521983A (ja) 2015-07-16 2018-08-09 バイオカイン セラピューティックス リミテッド がんを治療するための組成物および方法
EP3331919A1 (de) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Kombinationstherapie mit anti-ctla-4-antikörpern
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CA3082255A1 (en) 2016-11-23 2020-06-10 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
KR20190104048A (ko) 2017-01-06 2019-09-05 이오반스 바이오테라퓨틱스, 인크. 종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
IL268058B2 (en) 2017-01-20 2023-09-01 Magenta Therapeutics Inc Compositions and methods for depleting cd137 plus cells
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
PE20200757A1 (es) 2017-07-11 2020-07-27 Compass Therapeutics Llc Anticuerpos agonistas que se unen a cd137 humano y sus usos
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
TWI701259B (zh) * 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
SG11202004457XA (en) 2017-11-17 2020-06-29 Iovance Biotherapeutics Inc Til expansion from fine needle aspirates and small biopsies
EP3713961A2 (de) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
EP3737743A1 (de) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Verfahren zur erzeugung von til-produkten, die für tumorantigenspezifische t-zellen angereichert sind
CN111065652A (zh) * 2018-01-22 2020-04-24 江苏恒瑞医药股份有限公司 抗4-1bb抗体、其抗原结合片段及其医药用途
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
US20210137930A1 (en) 2018-02-13 2021-05-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
CA3094957A1 (en) 2018-03-29 2019-10-03 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20210230287A1 (en) * 2018-04-10 2021-07-29 Wuxi Biologics (Shanghai) Co., Ltd. A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof
BR112020021660A2 (pt) 2018-04-27 2021-02-02 Iovance Biotherapeutics, Inc. métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, composição de criopreservação
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
SG11202101787XA (en) 2018-09-20 2021-04-29 Iovance Biotherapeutics Inc Expansion of tils from cryopreserved tumor samples
BR112021008549A2 (pt) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
US20230039976A1 (en) 2018-11-05 2023-02-09 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
US20220033775A1 (en) 2018-11-05 2022-02-03 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathways inhibitors
AU2019374761A1 (en) 2018-11-05 2021-06-10 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP3898949A1 (de) 2018-12-19 2021-10-27 Iovance Biotherapeutics, Inc. Verfahren zur expansion tumorinfiltrierender lymphozyten unter verwendung von manipulierten cytokin-rezeptorenpaaren und deren verwendungen
KR20220002336A (ko) 2019-03-29 2022-01-06 미스트 쎄라퓨틱스, 엘엘씨 T 세포 치료제를 제조하기 위한 생체외 방법 및 관련 조성물 및 방법
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
AU2020320349A1 (en) * 2019-07-26 2022-02-17 Abl Bio Inc. Anti-EGFR/anti-4-1BB bispecific antibody and use thereof
CA3155727A1 (en) 2019-10-25 2021-04-29 Cecile Chartier-Courtaud Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2021108727A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Inc. Method of producing tumor-reactive t cell composition using modulatory agents
EP4073236A1 (de) 2019-12-11 2022-10-19 Iovance Biotherapeutics, Inc. Verfahren zur produktion von tumorinfiltrierenden lymphozyten (tils) und verfahren zur verwendung derselben
EP4107173A1 (de) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Verfahren zur expansion tumorinfiltrierender lymphozyten und deren verwendung
EP4110799A1 (de) 2020-02-27 2023-01-04 Myst Therapeutics, LLC Verfahren zur ex-vivo-anreicherung und expansion tumorreaktiver t-zellen und zugehörige zusammensetzungen davon
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
EP4146794A1 (de) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Verfahren zur herstellung von tumorinfiltrierenden lymphozyten und verwendungen davon in der immuntherapie
JP2023524108A (ja) 2020-05-04 2023-06-08 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
CA3185200A1 (en) * 2020-07-09 2022-01-13 Lankeanau Institute For Medical Research Compositions comprising antibodies to human ido-2
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CA3201818A1 (en) 2020-12-11 2022-06-16 Maria Fardis Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
WO2022187741A2 (en) 2021-03-05 2022-09-09 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions
BR112023021665A2 (pt) 2021-04-19 2023-12-19 Iovance Biotherapeutics Inc Método para tratar um câncer, e, composição
WO2022245754A1 (en) 2021-05-17 2022-11-24 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3226942A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3232700A1 (en) 2021-09-24 2023-03-30 Rafael CUBAS Expansion processes and agents for tumor infiltrating lymphocytes
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1994026290A1 (en) * 1993-05-07 1994-11-24 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
CA2172165C (en) * 1993-09-16 2003-12-02 Byoung S. Kwon Human receptor h4-1bb

Also Published As

Publication number Publication date
PT766745E (pt) 2003-02-28
JP2911056B2 (ja) 1999-06-23
JPH09509067A (ja) 1997-09-16
EP0766745B1 (de) 2002-10-23
DE69624436T2 (de) 2003-08-28
DK0766745T3 (da) 2002-11-25
ATE226641T1 (de) 2002-11-15
ES2185770T3 (es) 2003-05-01
EP0766745A1 (de) 1997-04-09
US5928893A (en) 1999-07-27
WO1996032495A1 (en) 1996-10-17

Similar Documents

Publication Publication Date Title
DE69624436T2 (de) Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
RU2205223C2 (ru) МОНОКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ αV-ИНТЕГРИНОВ (ВАРИАНТЫ), ЕГО ПОЛУЧЕНИЕ (ВАРИАНТЫ) И ИСПОЛЬЗОВАНИЕ, ГИБРИДОМА, ПОЛИПЕПТИД, ДНК
GB9503601D0 (en) Method of treatment and method of manufacture of medicament
EP1194164B8 (de) Prion protein peptide und deren verwendung
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
CA2220461A1 (en) Therapeutic compounds comprised of anti-fc receptor antibodies
EP0982988A4 (de) Im wesentlichen reines zonulin als physiologischer modulator von "tight junctions" bei säugern
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
BR9910396A (pt) Polinucleotìdeo(s) e polipeptìdeos basb029 a partirde neisseria meningitidis
GB9526178D0 (en) Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
IL122606A (en) (S)-hydroxa-nitrile-lyase
NO960510L (no) Fremgangsmåte for å fremstille små, diskrete, sfæriske addukter
ZA961450B (en) A process for the preparation of factor ix from biological sources
EP0769957A4 (de) Verfahren zur behandlung von motorischen defiziten
AU8866791A (en) Monoclonal antibody for use in diagnosing alzheimer's disease, hybridoma secreting said antibody and preparation method therefor
ATE221204T1 (de) Rezeptorbindungsassay, für den rezeptorbindungsassay geeigneter rekombinanter fusionsrezeptor, vektor zu dessen herstellung sowie reagenziensatz für die durchführung des rezeptorbindungsassays
DE69332637T2 (de) Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
BR0009358A (pt) Compostos
BR9911773A (pt) Compostos de moraxella catarrhalis
EP0832109A4 (de) Faktor-2, homolog zum fibroblasten-wachstumsfaktor und verfahren zu seiner anwendung
BR9911609A (pt) Proteìnas e genes de moraxella catarrhalis, antìgenos, anticorpos e usos
CA2038030A1 (en) Synthetic peptides which contain sequences from factor viia, and the use thereof
ATE328088T1 (de) Transketolase-verwandtes protein
TW288020B (en) Monoclonal antibodies specific to methamphetamine, hybridoma producing the antibodies, kits containing the antibodies and uses thereof
ES2088820A1 (es) Anticuerpos monoclonales antineumolisina.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee